ZA200603435B - Nucleic acids specifically binding bioactive ghrelin - Google Patents

Nucleic acids specifically binding bioactive ghrelin Download PDF

Info

Publication number: ZA200603435B
Authority: ZA; South Africa
Prior art keywords: ghrelin; nucleic acid; bioactive; detection; nucleic
Prior art date: 2003-11-10

Application number

ZA200603435A

Other languages

English (en)

Inventor

Klussmann Sven

Helmling Steffen

Eulberg Dirk

Maasch Christian

Buchner Klaus

Original Assignee

Noxxon Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-10

Filing date

2006-05-02

Publication date

2007-06-27

2006-05-02 Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag

2007-06-27 Publication of ZA200603435B publication Critical patent/ZA200603435B/en

Links

150000007523 nucleic acids Chemical class 0.000 title claims description 160
108020004707 nucleic acids Proteins 0.000 title claims description 158
102000039446 nucleic acids Human genes 0.000 title claims description 158
101800001586 Ghrelin Proteins 0.000 title claims description 140
230000000975 bioactive effect Effects 0.000 title claims description 49
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title claims description 47
230000027455 binding Effects 0.000 title claims description 45
238000009739 binding Methods 0.000 title claims description 45
102000012004 Ghrelin Human genes 0.000 title 1
238000000034 method Methods 0.000 claims description 55
108090000765 processed proteins & peptides Proteins 0.000 claims description 33
238000001514 detection method Methods 0.000 claims description 29
239000002253 acid Substances 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
230000003993 interaction Effects 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 14
230000005764 inhibitory process Effects 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 11
-1 n- octanoyl ghrelin Chemical compound 0.000 claims description 11
230000036528 appetite Effects 0.000 claims description 8
235000019789 appetite Nutrition 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
230000033228 biological regulation Effects 0.000 claims description 7
208000008589 Obesity Diseases 0.000 claims description 6
235000020824 obesity Nutrition 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 5
230000036772 blood pressure Effects 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
230000001404 mediated effect Effects 0.000 claims description 5
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
230000009918 complex formation Effects 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
230000004153 glucose metabolism Effects 0.000 claims description 4
102000004169 proteins and genes Human genes 0.000 claims description 4
108090000623 proteins and genes Proteins 0.000 claims description 4
208000027796 Blood pressure disease Diseases 0.000 claims description 3
208000030814 Eating disease Diseases 0.000 claims description 3
208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
235000014632 disordered eating Nutrition 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
108010090804 Streptavidin Proteins 0.000 claims description 2
239000008280 blood Substances 0.000 claims description 2
210000004369 blood Anatomy 0.000 claims description 2
230000000295 complement effect Effects 0.000 claims description 2
150000002500 ions Chemical class 0.000 claims description 2
102400000442 Ghrelin-28 Human genes 0.000 claims 45
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 18
229960002685 biotin Drugs 0.000 claims 9
235000020958 biotin Nutrition 0.000 claims 9
239000011616 biotin Substances 0.000 claims 9
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
229920001184 polypeptide Polymers 0.000 claims 4
108010087904 neutravidin Proteins 0.000 claims 3
BICGOULMPJLRQV-MYINAIGISA-N 1-[(2s,4s,5r)-2-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(Br)N1C(=O)NC(=O)C=C1 BICGOULMPJLRQV-MYINAIGISA-N 0.000 claims 2
108091023037 Aptamer Proteins 0.000 claims 2
108090001008 Avidin Proteins 0.000 claims 2
239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
229960005305 adenosine Drugs 0.000 claims 2
239000002738 chelating agent Substances 0.000 claims 2
208000018914 glucose metabolism disease Diseases 0.000 claims 2
238000001727 in vivo Methods 0.000 claims 2
230000005855 radiation Effects 0.000 claims 2
WYFYSTBFFDOVJW-UHFFFAOYSA-L 2-[4-[4-(3,5-diphenyltetrazol-2-ium-2-yl)phenyl]phenyl]-3,5-diphenyltetrazol-2-ium;dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC(=CC=2)C=2C=CC(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=NN1C1=CC=CC=C1 WYFYSTBFFDOVJW-UHFFFAOYSA-L 0.000 claims 1
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims 1
108020004414 DNA Proteins 0.000 claims 1
102000053602 DNA Human genes 0.000 claims 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
102000004190 Enzymes Human genes 0.000 claims 1
150000003838 adenosines Chemical class 0.000 claims 1
230000002596 correlated effect Effects 0.000 claims 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims 1
235000005686 eating Nutrition 0.000 claims 1
238000006911 enzymatic reaction Methods 0.000 claims 1
210000002381 plasma Anatomy 0.000 claims 1
210000002966 serum Anatomy 0.000 claims 1
BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 109
102100033367 Appetite-regulating hormone Human genes 0.000 description 94
239000002773 nucleotide Substances 0.000 description 37
125000003729 nucleotide group Chemical group 0.000 description 31
238000003556 assay Methods 0.000 description 13
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
229910052791 calcium Inorganic materials 0.000 description 12
239000011575 calcium Substances 0.000 description 12
230000000638 stimulation Effects 0.000 description 12
108091027076 Spiegelmer Proteins 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
150000001875 compounds Chemical class 0.000 description 10
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
238000002474 experimental method Methods 0.000 description 9
239000003446 ligand Substances 0.000 description 9
230000000694 effects Effects 0.000 description 8
239000005557 antagonist Substances 0.000 description 7
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 7
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
101100179594 Caenorhabditis elegans ins-4 gene Proteins 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
239000000122 growth hormone Substances 0.000 description 5
102000018997 Growth Hormone Human genes 0.000 description 4
108010051696 Growth Hormone Proteins 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
101150089655 Ins2 gene Proteins 0.000 description 4
238000000423 cell based assay Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000000580 secretagogue effect Effects 0.000 description 4
241000282412 Homo Species 0.000 description 3
101000888246 Homo sapiens Growth hormone secretagogue receptor type 1 Proteins 0.000 description 3
206010062767 Hypophysitis Diseases 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
210000005221 acidic domain Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000009510 drug design Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
210000003635 pituitary gland Anatomy 0.000 description 3
238000012216 screening Methods 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
101100179596 Caenorhabditis elegans ins-3 gene Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
208000014311 Cushing syndrome Diseases 0.000 description 2
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
206010020710 Hyperphagia Diseases 0.000 description 2
206010021118 Hypotonia Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
208000007379 Muscle Hypotonia Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
125000005313 fatty acid group Chemical group 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
229940121382 ghrelin analogues Drugs 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
241000894007 species Species 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
YQVMHOLUYGAYNG-UHFFFAOYSA-N 258338-12-4 Chemical compound C1CCC(C(=O)NC(CCC(O)=O)C(=O)NC(CC=2N=CNC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCC(O)=O)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N2C(CCC2)C(=O)N2C(CCC2)C(=O)NC(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCCNC(N)=N)C(O)=O)N1C(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CO)N(C(=O)CCCCCCC)C(=O)C(CO)NC(=O)CN)CC1=CC=CC=C1 YQVMHOLUYGAYNG-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000017265 ACTH-independent Cushing syndrome Diseases 0.000 description 1
101150034533 ATIC gene Proteins 0.000 description 1
101710111255 Appetite-regulating hormone Proteins 0.000 description 1
101100054570 Caenorhabditis elegans acn-1 gene Proteins 0.000 description 1
101100179824 Caenorhabditis elegans ins-17 gene Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000033485 Cushing syndrome due to ectopic ACTH secretion Diseases 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
102000000393 Ghrelin Receptors Human genes 0.000 description 1
108010016122 Ghrelin Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000997570 Homo sapiens Appetite-regulating hormone Proteins 0.000 description 1
208000037171 Hypercorticoidism Diseases 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000353097 Molva molva Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010034487 Pericarditis constrictive Diseases 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
101500028462 Rattus norvegicus Ghrelin Proteins 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
208000017515 adrenocortical insufficiency Diseases 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000006583 body weight regulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
208000000839 constrictive pericarditis Diseases 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
201000002091 ectopic Cushing syndrome Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
201000011523 endocrine gland cancer Diseases 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000000446 fuel Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
231100000508 hormonal effect Toxicity 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
229960003081 probenecid Drugs 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003893 regulation of appetite Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
239000004576 sand Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000004260 weight control Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Diabetes (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Plant Pathology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)

ZA200603435A 2003-11-10 2006-05-02 Nucleic acids specifically binding bioactive ghrelin ZA200603435B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03025743		2003-11-10

Publications (1)

Publication Number	Publication Date
ZA200603435B true ZA200603435B (en)	2007-06-27

Family

ID=34610046

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200603435A ZA200603435B (en)	2003-11-10	2006-05-02	Nucleic acids specifically binding bioactive ghrelin

Country Status (19)

Country	Link
US (2)	US20070031840A1 (cs)
EP (1)	EP1682662A1 (cs)
JP (1)	JP4823067B2 (cs)
KR (1)	KR20060125743A (cs)
CN (1)	CN1894407A (cs)
AP (1)	AP2006003618A0 (cs)
AU (1)	AU2004291656A1 (cs)
BR (1)	BRPI0415872A (cs)
CA (1)	CA2544805A1 (cs)
CR (1)	CR8388A (cs)
EA (1)	EA009376B1 (cs)
EC (1)	ECSP066559A (cs)
IL (1)	IL175443A0 (cs)
MA (1)	MA28153A1 (cs)
NO (1)	NO20062663L (cs)
OA (1)	OA13282A (cs)
TN (1)	TNSN06132A1 (cs)
WO (1)	WO2005049828A1 (cs)
ZA (1)	ZA200603435B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7750140B2 (en) *	2002-08-01	2010-07-06	Noxxon Pharma Ag	Ghrelin binding nucleic acids
EP2290071B1 (en)	2004-05-28	2014-12-31	Asuragen, Inc.	Methods and compositions involving microRNA
CA2857881A1 (en)	2004-11-12	2006-12-28	Asuragen, Inc.	Methods and compositions involving mirna and mirna inhibitor molecules
AR052741A1 (es) *	2005-04-08	2007-03-28	Noxxon Pharma Ag	Acidos nucleicos de union a ghrelin
WO2008036765A2 (en) *	2006-09-19	2008-03-27	Asuragen, Inc.	Micrornas differentially expressed in pancreatic diseases and uses thereof
JP2010510964A (ja) *	2006-09-19	2010-04-08	アシュラジェンインコーポレイテッド	治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
DK2104737T3 (da) *	2006-12-08	2013-05-27	Asuragen Inc	Funktioner og formål for let-7 mikro-RNAer
WO2008073915A2 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	Micrornas differentially expressed in leukemia and uses thereof
WO2008073920A2 (en) *	2006-12-08	2008-06-19	Asuragen, Inc.	Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) *	2006-12-29	2008-07-17	Asuragen, Inc.	Mir-16 regulated genes and pathways as targets for therapeutic intervention
US20090232893A1 (en) *	2007-05-22	2009-09-17	Bader Andreas G	miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) *	2007-05-22	2009-05-21	Bader Andreas G	miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
JP2010529966A (ja) *	2007-06-08	2010-09-02	アシュラジェンインコーポレイテッド	治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
US8361714B2 (en)	2007-09-14	2013-01-29	Asuragen, Inc.	Micrornas differentially expressed in cervical cancer and uses thereof
US20090186015A1 (en) *	2007-10-18	2009-07-23	Latham Gary J	Micrornas differentially expressed in lung diseases and uses thereof
US8071562B2 (en) *	2007-12-01	2011-12-06	Mirna Therapeutics, Inc.	MiR-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) *	2007-12-21	2009-07-09	Asuragen, Inc.	Mir-10 regulated genes and pathways as targets for therapeutic intervention
US20090263803A1 (en) *	2008-02-08	2009-10-22	Sylvie Beaudenon	Mirnas differentially expressed in lymph nodes from cancer patients
EP2268832A2 (en) *	2008-03-06	2011-01-05	Asuragen, INC.	Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) *	2008-03-26	2011-01-12	Asuragen, INC.	Compositions and methods related to mir-16 and therapy of prostate cancer
US8258111B2 (en)	2008-05-08	2012-09-04	The Johns Hopkins University	Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20100179213A1 (en) *	2008-11-11	2010-07-15	Mirna Therapeutics, Inc.	Methods and Compositions Involving miRNAs In Cancer Stem Cells
EP2493910A1 (en)	2009-10-30	2012-09-05	Tranzyme Pharma, Inc.	Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
AU2012206750A1 (en) *	2011-01-10	2013-07-18	Noxxon Pharma Ag	Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2013040251A2 (en)	2011-09-13	2013-03-21	Asurgen, Inc.	Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614395A (en) *	1988-03-08	1997-03-25	Ciba-Geigy Corporation	Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
EP0786469B1 (en) *	1990-06-11	2006-03-01	Gilead Sciences, Inc.	Methods of use of nucleic acid ligands
JPH11505527A (ja) *	1995-05-03	1999-05-21	ホワイトヘッドインスティチュートフォーバイオメディカルリサーチ	鏡像異性体リガンドの同定
US5780221A (en) *	1995-05-03	1998-07-14	Whitehead Institute For Biomedical Research	Identification of enantiomeric ligands
US20030211967A1 (en) *	2001-05-07	2003-11-13	Bryant Henry Uhlman	Method for selectively inhibiting ghrelin action
AU2001259056A1 (en) *	2000-05-17	2001-11-26	Eli Lilly And Company	Method for selectively inhibiting ghrelin action
CA2411667A1 (en) *	2000-05-30	2001-12-06	Merck & Co. Inc.	Ghrelin analogs
US7750140B2 (en) *	2002-08-01	2010-07-06	Noxxon Pharma Ag	Ghrelin binding nucleic acids
AR052741A1 (es) *	2005-04-08	2007-03-28	Noxxon Pharma Ag	Acidos nucleicos de union a ghrelin

2004
- 2004-11-10 OA OA1200600147A patent/OA13282A/en unknown
- 2004-11-10 EA EA200600735A patent/EA009376B1/ru not_active IP Right Cessation
- 2004-11-10 AP AP2006003618A patent/AP2006003618A0/xx unknown
- 2004-11-10 BR BRPI0415872-5A patent/BRPI0415872A/pt not_active IP Right Cessation
- 2004-11-10 WO PCT/EP2004/012739 patent/WO2005049828A1/en not_active Ceased
- 2004-11-10 KR KR1020067009024A patent/KR20060125743A/ko not_active Withdrawn
- 2004-11-10 CA CA002544805A patent/CA2544805A1/en not_active Abandoned
- 2004-11-10 US US10/578,938 patent/US20070031840A1/en not_active Abandoned
- 2004-11-10 CN CNA2004800377977A patent/CN1894407A/zh active Pending
- 2004-11-10 JP JP2006538786A patent/JP4823067B2/ja not_active Expired - Fee Related
- 2004-11-10 AU AU2004291656A patent/AU2004291656A1/en not_active Abandoned
- 2004-11-10 EP EP04797787A patent/EP1682662A1/en not_active Ceased
2006
- 2006-05-02 ZA ZA200603435A patent/ZA200603435B/en unknown
- 2006-05-04 IL IL175443A patent/IL175443A0/en unknown
- 2006-05-09 TN TNP2006000132A patent/TNSN06132A1/fr unknown
- 2006-05-10 EC EC2006006559A patent/ECSP066559A/es unknown
- 2006-05-10 MA MA29015A patent/MA28153A1/fr unknown
- 2006-05-10 CR CR8388A patent/CR8388A/es not_active Application Discontinuation
- 2006-06-09 NO NO20062663A patent/NO20062663L/no not_active Application Discontinuation
2010
- 2010-02-24 US US12/711,415 patent/US20100261291A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AP2006003618A0 (en)	2006-06-30
JP4823067B2 (ja)	2011-11-24
KR20060125743A (ko)	2006-12-06
BRPI0415872A (pt)	2007-01-09
EP1682662A1 (en)	2006-07-26
AU2004291656A1 (en)	2005-06-02
WO2005049828A1 (en)	2005-06-02
CR8388A (es)	2006-10-17
JP2007513608A (ja)	2007-05-31
US20070031840A1 (en)	2007-02-08
CA2544805A1 (en)	2005-06-02
OA13282A (en)	2007-01-31
ECSP066559A (cs)	2006-11-24
TNSN06132A1 (fr)	2007-11-15
US20100261291A1 (en)	2010-10-14
NO20062663L (no)	2006-08-09
EA200600735A1 (ru)	2006-10-27
MA28153A1 (fr)	2006-09-01
CN1894407A (zh)	2007-01-10
EA009376B1 (ru)	2007-12-28
IL175443A0 (en)	2006-09-05

Publication	Publication Date	Title
ZA200603435B (en)	2007-06-27	Nucleic acids specifically binding bioactive ghrelin
US8101734B2 (en)	2012-01-24	Ghrelin binding nucleic acids
US20120083520A1 (en)	2012-04-05	Ghrelin binding nucleic acids
AU2010259549B2 (en)	2015-10-01	Aptamer for chymase, and use thereof
AU2010284329A1 (en)	2012-03-29	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
AU2008303775A1 (en)	2009-04-02	C5a binding nucleic acids
US8383789B2 (en)	2013-02-26	Vasopressin-binding L-nucleic acid
ES2368041T3 (es)	2011-11-11	Ácidos nucleicos de unión a ghrelina.
HK1097879A (en)	2007-07-06	Nucleic acids specifically binding bioactive ghrelin
AU2012216540A1 (en)	2012-09-20	Ghrelin binding nucleic acids
HK1117567A (en)	2009-01-16	Ghrelin binding nucleic acids
C-peptide et al.	2006	ABBS 2005, 38 (08): Human Proinsulin C-peptide from a Precursor Overexpressed in Pichia pastoris